Vaccination with myelin oligodendrocyte glycoprotein adsorbed to alum effectively protects DBA/1 mice from experimental autoimmune encephalomyelitis

被引:9
作者
Wållberg, M [1 ]
Wefer, J [1 ]
Harris, RA [1 ]
机构
[1] Karolinska Inst, Ctr Mol Med, Stockholm, Sweden
关键词
EAE; MOG; alum; mouse; vaccination;
D O I
10.1002/eji.200323772
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To prevent an organism from developing autoimmunity the body limits the number of autoreactive cells through thymic negative selection and regulates their activity through induction of suppressor T cells. Development of antigen-specific therapies provides an interesting opportunity to imitate the body's own, often effective, method of protection. Our study demonstrates that DBA/1 mice could be protected from experimental autoimmune encephalomyelitis induced through injection of recombinant myelin oligodendrocyte glycoprotein (rMOG) when they were previously immunized intraperitoneally with rMOG adsorbed to aluminium hydroxide. This protection was associated with a decreased IFN-gamma production by rMOG-specific cells, but not a decreased proliferative response. Protection was long lasting, indicating that MOG-alum vaccination might be developed as a prophylactic therapy in multiple sclerosis.
引用
收藏
页码:1539 / 1547
页数:9
相关论文
共 45 条
[1]   Screening of several H-2 congenic mouse strains identified H-2q mice as highly susceptible to MOG-induced EAE with minimal adjuvant requirement [J].
Abdul-Majid, KB ;
Jirholt, J ;
Stadelmann, C ;
Stefferl, A ;
Kjellén, P ;
Wallström, E ;
Holmdahl, R ;
Lassmann, H ;
Olsson, T ;
Harris, RA .
JOURNAL OF NEUROIMMUNOLOGY, 2000, 111 (1-2) :23-33
[2]   Fc receptors are critical for autoimmune inflammatory damage to the central nervous system in experimental autoimmune encephalomyelitis [J].
Abdul-Majid, KB ;
Stefferl, A ;
Bourquin, C ;
Lassmann, H ;
Linington, C ;
Olsson, T ;
Kleinau, S ;
Harris, RA .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2002, 55 (01) :70-81
[3]   Oral treatment of mice with copolymer 1 (glatiramer acetate) results in the accumulation of specific Th2 cells in the central nervous system [J].
Aharoni, R ;
Meshorer, A ;
Sela, M ;
Arnon, R .
JOURNAL OF NEUROIMMUNOLOGY, 2002, 126 (1-2) :58-68
[4]  
AMOR S, 1994, J IMMUNOL, V153, P4349
[5]   MULTIPLE LEVELS OF PERIPHERAL TOLERANCE [J].
ARNOLD, B ;
SCHONRICH, G ;
HAMMERLING, GJ .
IMMUNOLOGY TODAY, 1993, 14 (01) :12-14
[6]   IMMUNOSUPPRESSIVE THERAPY OF AUTOIMMUNE-DISEASES (REPRINTED FROM TRENDS IN PHARMACOLOGICAL SCIENCES, VOL 14, PG 213-217, 1993) [J].
BACH, JF .
IMMUNOLOGY TODAY, 1993, 14 (06) :322-326
[7]   Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand [J].
Bielekova, B ;
Goodwin, B ;
Richert, N ;
Cortese, I ;
Kondo, T ;
Afshar, G ;
Gran, B ;
Eaton, J ;
Antel, J ;
Frank, JA ;
McFarland, HF ;
Martin, R .
NATURE MEDICINE, 2000, 6 (10) :1167-1175
[8]   ISOLATION OF MYELIN BASIC PROTEIN-REACTIVE T-CELL LINES FROM NORMAL HUMAN-BLOOD [J].
BURNS, J ;
ROSENZWEIG, A ;
ZWEIMAN, B ;
LISAK, RP .
CELLULAR IMMUNOLOGY, 1983, 81 (02) :435-440
[9]   REGULATORY T-CELL CLONES INDUCED BY ORAL TOLERANCE - SUPPRESSION OF AUTOIMMUNE ENCEPHALOMYELITIS [J].
CHEN, YH ;
KUCHROO, VK ;
INOBE, J ;
HAFLER, DA ;
WEINER, HL .
SCIENCE, 1994, 265 (5176) :1237-1240
[10]   What are the limits of adjuvanticity? [J].
Del Giudice, G ;
Podda, A ;
Rappuoli, R .
VACCINE, 2001, 20 :S38-S41